FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy and safety of efgartigimod in the treatment of impending myasthenic crisis. PMID 41909657 · Front Immunol · 2026 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ruxolitinib treatment in patients with polycythemia vera reduces JAK2 variant allele frequency and improves symptom burden and hematocrit control. PMID 41890273 · Ther Adv Hematol · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and feasibility of a layered embolization strategy with drug-eluting and uniform-caliber microspheres for advanced hepatocellular carcinoma and unresectable liver metastases: a prospective single-arm clinical trial. PMID 41889406 · Front Oncol · 2026 The study is a prospective single-arm trial, not randomized. It does not report a Phase III or Phase II/III designation. Most importantly, it lacks any primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The efficacy endpoints are limited to short-term imaging response (disease control rate) and biomarker dynamics, which are not time-to-event outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Effect of Breast Cancer and Breast Self-Examination Health Education on Awareness, Beliefs, and Practices of Female Students at the Faculty of Health Sciences of a University in Somalia. PMID 41885785 · Breast J · 2026 Eligible for oncology, human, randomized, and original results, but excluded due to lack of drug intervention and time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Symptom relief and cytokine modulation by clarithromycin in mild COVID-19 pneumonia: an exploratory, multicenter, randomized-controlled open-label trial (CAME-COVID study). PMID 41884792 · Ther Adv Infect Dis · 2026 The study is a randomized controlled trial of clarithromycin for COVID-19 pneumonia, not an oncology (human malignant neoplasm) study. It lacks a Phase III designation and does not report a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and health-related quality of life associated with second-line vedolizumab after first-line treatment with one anti-TNF in patients with ulcerative colitis: a meta-analysis of the GEMINI-1 and VISIBLE-1 trials. PMID 41883697 · Ther Adv Gastroenterol · 2026 The record is a meta-analysis of ulcerative colitis trials, which is non-oncology, and focuses on clinical remission as the primary endpoint, not a time-to-event outcome like OS or PFS. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of Ropivacaine-Based Thoracic Paravertebral Block versus Erector Spinae Plane Block on Quality of Recovery in Laparoscopic Colorectal Cancer Surgery: A Randomized Controlled Trial. PMID 41873336 · Drug Des Devel Ther · 2026 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma in Non-Endemic Regions: A Single-Arm Phase 2 Clinical Trial. PMID 41859748 · Cancer Manag Res · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Implementing a successful patient navigation program for follow-up colonoscopy: Lessons from the PRECISE study. PMID 41849281 · PLoS One · 2026 The record describes a randomized trial of a patient navigation intervention to improve colonoscopy completion rates after abnormal FIT screening, not a drug trial. It lacks the required drug intervention and time-to-event efficacy endpoint (OS/PFS/DFS/etc., HR, Kaplan-Meier) for inclusion in the oncology KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Amino Acid-Based Enteral Nutrition Enhances Postoperative Recovery in Colorectal Cancer Patients: A Randomized Controlled Trial. PMID 41848576 · Nutr Cancer · 2026 The study is a randomized controlled trial in human colorectal cancer patients, but it is excluded because: 1) it evaluates nutritional formulas, not a drug intervention; 2) no Phase III/IIIb or Phase II/III classification is provided (phase unclear); 3) the primary endpoints are nutritional, recovery, and safety metrics, not time-to-event oncology efficacy endpoints (e.g., OS, PFS, DFS). Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Qu-Shi-Jie-Du Decoction for Prevention of Recurrence and Metastasis in High-Risk Stage II/III Colon Cancer: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial. PMID 41810508 · Integr Cancer Ther · 2026 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Partially covered or uncovered metal stent efficacy in malignant unresectable distal biliary obstruction (METARSI): Randomized multicenter trial. PMID 41777335 · Endosc Int Open · 2026 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Quality of Recovery After Laparoscopic Ovarian Cystectomy: A Randomized Controlled Trial Comparing Opioid-Free Multimodal Analgesia Versus Opioid-Based Anesthesia. PMID 41773363 · Clin Ter · 2026 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Hybrid Machine Learning Method and Standard Data Analysis Approaches for Predicting Treatment Outcomes of Cardiovascular Diseases: A Randomized Controlled Trial. PMID 41773358 · Clin Ter · 2026 The study is not in oncology and does not involve a drug intervention, which are mandatory criteria for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Intertransverse Process Block versus Erector Spinae Plane Block as Adjuncts to an Interpectoral Block for Breast Cancer Surgery: A Randomized Controlled Trial. PMID 41768106 · J Pain Res · 2026 The trial is a randomized, oncology (breast cancer) study but evaluates anesthetic techniques, not a drug intervention for efficacy. The primary endpoint is morphine consumption (a safety/efficacy measure), not a time-to-event endpoint like OS or PFS. Therefore, it does not meet the core eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The effectiveness of the AI-based RehabLung mobile rehabilitation system on cardiopulmonary function and user satisfaction in lung cancer patients undergoing thoracic surgery: a protocol for a two-arm randomized clinical trial. PMID 41762649 · Ther Adv Respir Dis · 2026 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A short-term, exploratory randomized controlled trial on the safety and feasibility of intraoperative raltitrexed peritoneal chemotherapy in laparoscopic radical resection for advanced colorectal cancer. PMID 41737519 · Front Surg · 2026 The study is an exploratory randomized trial in oncology with a drug intervention, but it is not a Phase III or definitive trial, and its primary endpoints are safety/feasibility, not a time-to-event efficacy endpoint required for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass). PMID 41732658 · Ther Adv Med Oncol · 2026 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies. PMID 41710044 · Rheumatol Adv Pract · 2026 The study is a randomized Phase 3 trial with a drug intervention (bimekizumab) and reports original results, but it is not an oncology trial (psoriatic arthritis) and does not include a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoints are patient-reported outcomes (EQ-5D-3L) and work productivity (WPAI-SHP), which are not time-to-event survival outcomes. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial. PMID 41709925 · Ther Adv Med Oncol · 2026 The trial is explicitly a randomized, multicenter, noninferiority study with PFS as primary endpoint and OS as key secondary, meeting definitive Phase III-like criteria for oncology drug intervention. The report is an original journal article with efficacy results. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 1 Figure · 2 Panel · risk visible |
| Sucralose as a Way to Enhance Regulatory T Cells, the SWEET Trial: Clinical Research Protocol. PMID 41694241 · Can J Kidney Health Dis · 2026 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Acupuncture combined with immunotherapy for recurrent and metastatic cervical cancer: a pilot RCT protocol. PMID 41684588 · Front Oncol · 2026 The record is a protocol for a randomized trial in cervical cancer, which meets oncology, human, randomized, and drug intervention criteria. However, it does not present results; it is a protocol. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III (it is described as a 'pilot' and 'first' RCT, which does not establish definitive-phase evidence). The primary endpoint (ORR) is not a time-to-event endpoint, though PFS and OS are listed as secondary endpoints. Therefore, it is excluded as a protocol without results and due to unclear phase. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| KRAS p.G12C mutated-targeted treatments in metastatic colorectal cancer: a systematic review and meta-analysis. PMID 41612983 · Ann Gastroenterol · 2026 The record is a systematic review and meta-analysis of multiple early-phase trials, not an original report of a single Phase III/IIIb or Phase II/III randomized trial. The abstract does not report any time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or Kaplan-Meier/HR data. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomised pilot trial of perioperative propranolol combined with celecoxib versus standard of care in stage III melanoma: The ProCel study protocol. PMID 41610103 · PLoS One · 2026 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Digital health interventions for cervical cancer screening among hard-to-reach women in health-resource-limited areas: Protocol for a controlled trial with historical controls and two randomised intervention arms. PMID 41602939 · Digit Health · 2026 This is a protocol for a randomized controlled trial evaluating a digital health intervention (web/WeChat platform) for cervical cancer screening, not a drug intervention. It reports no efficacy results (Kaplan-Meier, HR, time-to-event endpoints) and is a Phase not specified as III/IIIb or II/III. Therefore, it does not meet the eligibility criteria for inclusion in the KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjuvant Chemotherapy with Traditional Chinese Herbal Granules Versus Placebo in Resected Non-Small Cell Lung Cancer: Updated Survival Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. PMID 41589575 · Integr Cancer Ther · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions. PMID 41526135 · Handb Clin Neurol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized trial of dose de-escalation in low-risk prostate cancer patients implanted with Pd-103. PMID 41494910 · Brachytherapy · 2026 The study is a randomized trial with a primary time-to-event endpoint (biochemical failure) for human prostate cancer. However, it fails the drug intervention criterion because the intervention is brachytherapy (a radioisotope treatment), not a systemic drug therapy. The phase of the trial is not explicitly stated in the provided metadata as Phase III/IIIb or Phase II/III, but even if it were, the absence of a drug intervention makes it ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma. PMID 41453647 · Ann Hepatol · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Frontline Pembrolizumab or Methotrexate in Elderly, Frail, or Cisplatin-Ineligible Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase 2 Study ELDORANDO (AIO-KHT-0115). PMID 41428603 · Oncol Res Treat · 2026 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Study on the Improvement of Quality of Survival in Cervical Cancer Patients after Chemoradiotherapy through an Integrated Traditional Chinese and Western Medicine Therapy Based on a Syndrome Differentiation-Driven Dynamic Intervention Strategy. PMID 41343416 · Oncology · 2026 The study is a randomized oncology trial reporting primary OS results via Kaplan-Meier and Cox regression, but the intervention is a non-drug-only regimen (integrated Chinese and Western medicine therapy without specified drug-containing component), and the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Translated article] Network meta-analysis of perioperative immunotherapies in non-small-cell lung cancer according to tumor programmed death ligand 1 expression. PMID 41188103 · Farm Hosp · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparative Efficacy of all Available Pharmaceutical Therapies for Moderate to Severe Crohn's Disease: A Systematic Review and Network Meta-Analysis. PMID 41140764 · Gastro Hep Adv · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| ConquerFear-HK: A Randomized Controlled Trial of a Metacognition-Based, Manualized Intervention for Fear of Cancer Recurrence among Chinese Cancer Survivors. PMID 40784346 · Psychother Psychosom · 2026 The study is an oncology randomized controlled trial reporting original results, but it is ineligible because it lacks a drug intervention and its primary endpoint is not a time-to-event efficacy measure. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Volumetric Changes and Acute Toxicity With 68Ga Prostate-Specific Membrane Antigen Versus 18F-Fluciclovine Positron Emission Tomography/Computer Tomography Guided Postprostatectomy Radiation: Final Analysis of a Randomized Trial. PMID 40738247 · Pract Radiat Oncol · 2026 The report is a primary, randomized, human oncology trial, but it is excluded because it lacks a time-to-event efficacy endpoint and does not involve a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Bayesian model averaging for randomized dose optimization trials in multiple indications. PMID 39930766 · J Biopharm Stat · 2026 The record describes a statistical methodology paper proposing a Bayesian model averaging approach for dose optimization in randomized Phase III trials. While it references oncology, humans, randomization, and Phase III, it does not report or analyze any clinical trial results with a time-to-event efficacy endpoint. It is a simulation study, not an original clinical trial result report. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Combination of Danggui Buxue Tang and concurrent chemoradiotherapy improves treatment outcomes by strengthening B cell immunity in patients with nasopharyngeal carcinoma-a double-blind, randomized trial. PMID 41158262 · Transl Cancer Res · 2025-Sep-30 The record is a randomized trial in human oncology with a drug intervention, but it fails two key eligibility criteria: 1) it does not establish a definitive Phase III/IIIb or Phase II/III designation (the phase is unspecified, but the small sample size and primary endpoint suggest an early-phase exploratory trial), and 2) it lacks a time-to-event efficacy endpoint. The primary endpoint is adverse effects and compliance, which is a safety/tolerability endpoint, not an efficacy endpoint. The secondary endpoints focus on TCM constitution and gene expression, with no mention of survival or progression-free time-to-event outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Multimodal prehabilitation to prevent loss of cardiorespiratory fitness in patients with locally advanced lung cancer undergoing chemoimmunotherapy: protocol for a non-randomized multicentre study. PMID 41133003 · Transl Lung Cancer Res · 2025-Sep-30 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effect of Aspirin on Development of First and Recurrent Primary Cutaneous Keratinocyte Carcinomas in Older Australian Adults: Extended Follow-up of a Large Randomised Controlled Trial. PMID 41112419 · J Cancer Prev · 2025-Sep-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of liposomal bupivacaine combined with bupivacaine hydrochloride for transversus thoracic muscle plane block and pectoral nerves block in modified radical mastectomy for breast cancer: protocol for a randomised controlled trial. PMID 41033778 · BMJ Open · 2025-Sep-30 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Investigation of prophylactic clip haemorrhage control for colorectal cold snare polypectomy in patients taking antithrombotic drugs (PERCOLD): study protocol-a multicentre prospective parallel-group non-inferiority RCT phase 3 trial. PMID 41033774 · BMJ Open · 2025-Sep-30 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Postoperative bladder training in patients with mid-low rectal cancer facilitates early removal of the urinary catheter: a prospective, randomized, open-label, blinded-endpoint trial. PMID 41029750 · World J Surg Oncol · 2025-Sep-30 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Impact of early blood purification on serum inflammatory mediators and hemorheology in severe acute pancreatitis. PMID 41024315 · Hereditas · 2025-Sep-29 The study is a randomized trial in humans with a primary clinical endpoint, but it is not an oncology study (severe acute pancreatitis). The intervention is a non-drug procedure (blood purification/hemodiafiltration). No time-to-event efficacy endpoint (OS, PFS, etc.) or Kaplan-Meier/HR analysis is reported. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A feasibility study of scheduling a remission consultation in the management of patients treated for localized breast cancer. PMID 41024190 · BMC Psychol · 2025-Sep-29 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Evaluating the effectiveness of a risk prediction model (PERSARC) on improving treatment decisions quality for patients with soft-tissue sarcomas: the VALUE-PERSARC study. PMID 41023919 · BMC Med Inform Decis Mak · 2025-Sep-29 The study is an oncology randomized trial in humans, but it does not meet key eligibility criteria. It lacks a primary/key secondary time-to-event efficacy endpoint (the primary outcome is decision-making quality, not survival or progression). Furthermore, the intervention is a risk prediction model (PERSARC) to support decision-making, not a drug-containing intervention. The phase is also not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer. PMID 41022779 · NPJ Breast Cancer · 2025-Sep-29 The record describes a biomarker analysis (tsMHC-II expression) from a phase III randomized trial (NeoTRIP). While it is oncology, human, randomized, phase III, and involves a drug intervention, the primary endpoint analyzed is pathological complete response (pCR), which is not a time-to-event endpoint. The report is a subgroup/biomarker analysis, not the primary trial report. Therefore, it does not meet the required criterion for a time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial. PMID 41016926 · Signal Transduct Target Ther · 2025-Sep-29 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparison of ultrasound-guided continuous intertransverse process block and continuous erector spinae plane block for postoperative analgesia after uniportal video-assisted thoracoscopic surgery: protocol for a double-blind, prospective, randomised controlled trial. PMID 41022450 · BMJ Open · 2025-Sep-28 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effects of preoperative immunonutrition vs standard oral nutrition in patients undergoing colorectal surgery: A randomized controlled trial. PMID 41024777 · World J Gastrointest Surg · 2025-Sep-27 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Alzheimer's disease outlook: controversies and future directions. PMID 40997840 · Lancet · 2025-Sep-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |